短肠综合征患者的口服抗菌剂:值得一试!
Julia W Korzilius1, Michelle Gompelman1, Guus T J Wezendonk1
1Department of Gastroenterology and Hepatology, Radboud university medical center, Nijmegen, the Netherlands.
The Journal of antimicrobial chemotherapy
|June 30, 2023
概括
在短肠综合征 (SBS) 患者中,口服抗菌素的生物可用性有显著的变化. 一些药物呈现出比预期更好的吸收,但治疗药物监测对于SBS的有效治疗至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 临床药房 临床药房
背景情况:
- 在短肠综合征 (SBS) 中,口服抗菌素的使用因胃肠解剖学变化而复杂,影响药物吸收和生物可用性.
- 有限的前性数据存在于SBS患者口服抗菌剂的生物可用性.
研究的目的:
- 在短肠综合征 (SBS) 患者中确定常用的抗微生物药物的口服生物可用性.
- 为指导SBS感染治疗的临床决策.
主要方法:
- 一项探索性临床研究评估了SBS肠道衰竭患者中克林达米辛,西普罗素,克西林和可纳的药理动力学 (PK).
- 参与者同时接受了两种药物的单次口服和静脉注射剂,在药物注射后长达12小时进行了密集的PK采样.
主要成果:
- 生物利用度的中位数有所不同:西普罗夫洛克萨辛 (36%),克洛克萨西林 (50%),克林达米辛 (93%) 和可纳 (98%).
- 对所有药物的生物可用性观察到显著的患者间变异.
结论:
- 在一些SBS患者中,选择的口服抗微生物生物利用率超过了预期,表明了潜在的治疗可行性.
- 由于患者间的高变异性,建议对SBS患者进行治疗药物监测,以确保足够的药物暴露.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
162
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
162
Antimicrobial Effectiveness
55
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
55
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
563
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
563
Combined Effects of Drugs: Synergism
4.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.1K


